AVBP
ArriVent BioPharma, Inc.
13.51
+0.02 (+0.11%)
52w low 11.36
35.83 high
8.8% of range
Financial Analysis
| (USD) | Mar 25 | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Total Revenue | -- | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | -- | 33.62M | 38.32M | 38.82M | 46.11M | 52.69M | |
| R&D | -- | 27.72M | 32.17M | 32.17M | 37.62M | 42.34M | |
| SG&A | -- | 5.90M | 6.15M | 6.65M | 8.49M | 10.35M | |
| Operating Income | -- | -33.62M | -38.32M | -38.82M | -46.11M | -52.69M | |
| EBITDA | -- | -33.62M | -38.32M | -38.82M | -46.11M | -52.69M | |
| Pretax Income | -- | -31.40M | -34.98M | -35.54M | -43.32M | -49.89M | |
| Net Income | -- | -31.40M | -34.98M | -35.54M | -43.32M | -49.89M | |
| EPS Diluted | -1.90 | -0.90 | -0.83 | -- | -0.96 | -1.05 | |
| Diluted Shares | 33.90M | 35.01M | 41.91M | -- | 45.07M | 47.61M |
Revenue CAGR
--
Net Income CAGR
--
EPS CAGR
--
FCF CAGR
--
Revenue YoY
--